- Home
- MPU vs HOWL Comparison
MPU vs HOWL Comparison
Compare MPU & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | HOWL |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 15.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPU | HOWL |
|---|---|---|
| Price | $0.25 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 213.0K | ★ 1.0M |
| Earning Date | 04-16-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.27 |
| 52 Week High | $4.44 | $2.23 |
Technical Indicators
Market Signals| Indicator | MPU | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 45.16 |
| Support Level | $0.21 | $0.36 |
| Resistance Level | $0.32 | $0.76 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 20.53 | 53.28 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.